GLAXO Stock View

GlaxoSmithKline Pharmaceuticals Ltd
stock-view-header

₹ 1,548.25

icon 37.60 | 2.49
Market Cap ₹( Cr.)
262,282.90
Proj. P/E (x)
42.84
Proj. P/BV (x)
14.14
Proj. ROE (%)
33.60
Proj EV / EBITDA (x)
--
Proj. Revenue ( Cr.)
33,860.60

Stock View

HOLD

Last Updated On.
24-Sep-2023
 

The average score for GlaxoSmithKline Pharmaceuticals Ltd stands at 6 against 4, three months back.

GlaxoSmithKline Pharmaceuticals Limited is an India-based global healthcare company. The Company is engaged in the business of manufacturing, distributing and trading in pharmaceuticals. It has three product areas: vaccines, specialty and general medicines. Its general medicines business has a portfolio of medicines in anti-infectives, pain, dermatology and vitamins. Its general medicines brands include Augmentin, Calpol, Ceftum, Eltroxin, CCM, Neosporin, Betnovate, T-bact and Physiogel. Its T-bact brand products are used in specific types of bacterial skin infections. The Company's vaccine brands include Shingrix, Infanrix Hexa, Synflorix, Boostrix, Havrix, Menveo, Fluarix Tetra and Varilrix. Its specialty medicines business is focused on developing medicines for respiratory diseases and human immunodeficiency virus. The Company is also building its presence in other therapeutic areas, such as immunology and oncology. Its specialty medicines brands include Nucala and Trelegy Ellipta.

Disclaimer : All estimates (1 year forward) are based on Consensus View provided by Refinitiv.


Technical Data

50 DMA(₹)
1,446.29
100 DMA(₹)
1,406.64
200 DMA(₹)
1,346.79
52 Weeks Range
1,228.00     1,622.95

Invest wise with Expert advice

mobile icon
  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required